Open House Rebate Agreements for Formoterol, Glycopyrronium Bromide and Beclometasone, ATC R03AL09

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jun 03, 2027 · 279 days left·Open·Supplies·Framework

Structured notice only

Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol, Glycopyrroniumbromid und Beclometason, ATC R03AL09

40/100

Opportunity Score

Needs reviewLow complexity

SuppliesFrameworkOpen

Why this score?

Opportunity

40 / 100

Complexity

20 / 100

Risk factors

Structured data indicates EU funding (isEuFunded: true) but XML notice states no EU funds (FundingProgramCode: no-eu-fu...

The open-house model is explicitly not subject to procurement law; legal remedies may differ. The notice includes a not...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Overview

Moderate opportunity

Key Facts

Framework procurement
Supplies contract
1 lot
Duration until Jul 2027
Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Formoterol, Glycopyrroniumbromid, and Beclometason (ATC R03AL09).
Contract duration from earliest start (August 1, 2025) to July 31, 2027.

Show full summary

This is an Open House model by AOK Bayern for non-exclusive rebate agreements on pharmaceutical products with active substances Formoterol, Glycopyrroniumbromid, and Beclometason (ATC R03AL09). Any qualified pharmaceutical company can join; no competitive selection. The contracts run from August 1, 2025 to July 31, 2027, with possible early termination. Submissions can be in paper or with qualified electronic signature. No estimated contract value is provided.

Risks

Structured data indicates EU funding (isEuFunded: true) but XML notice states no EU funds (FundingProgramCode: no-eu-fu...

The open-house model is explicitly not subject to procurement law; legal remedies may differ. The notice includes a not...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

Proof of authorization (commercial register extract or power of attorney).

Eligibility

Only pharmaceutical companies are eligible.

Administrative

Submission of signed contract, annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and self-declaration of reliability.

Requirements may be incomplete.

Buyer

Name

AOK Bayern - Die Gesundheitskasse

Location

München, DEU

[email protected]

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open House Rebate Agreements for Formoterol, Glycopyrronium Bromide and Beclometasone, ATC R03AL09

Non-exclusive rebate agreements for the specified pharmaceutical products. Open to all interested pharmaceutical companies meeting eligibility criteria. Contract duration: 24 months from earliest start date.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

Jul 2025 - Jul 2027

Procurement Details

Publication date: 15 Jun 2025
Languages: German

Reference metadata

Legal basis: 32014L0024

Reference IDs

Tender ID: 386697-2025

Documents (2)

Procurement document 1 Submission portal 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3